Global partners in the diabetes segment, Boehringer Ingelheim and Lilly, have entered into an India-specific co-promotion deal for a basket of diabetes compounds in both late-stage development or on the market, adding to the string of such alliances in the country.
The collaboration includes Boehringer Ingelheim's oral antidiabetic agent linagliptin, which has yet to be approved for marketing in India, and...






![Spotlight On RDCs, AOCs As Leading Novel Bioconjugates[Updated]](https://web.insights.norstella-labs.com/resizer/v2/3M7ZAWZOBNK7NG4A4WDOIFG6DU.jpg?smart=true&auth=392a1fdb3cfacb29445720c412410e598dbcc5f90f14857652cd498bd0faa0fb&width=400&height=225)
